Overview

Description

  • NatureSynthetic
  • Amino Acid Sequence
    • SpeciesHuman
    • SequenceLKACYYQIQREKLN
    • Amino acids1644 to 1657

Associated products

Specifications

Our Abpromise guarantee covers the use of ab22998 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-Als2 antibody (ab4155)

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

General Info

  • Alternative names
    • ALS 2
    • ALS2
    • ALS2_HUMAN
    • ALS2CR6
    • Alsin
    • ALSJ
    • Amyotrophic lateral sclerosis 2 (juvenile)
    • Amyotrophic lateral sclerosis 2 (juvenile) chromosome region candidate 6
    • Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 6 protein
    • Amyotrophic lateral sclerosis 2 protein
    • Amyotrophic lateral sclerosis protein 2
    • FLJ31851
    • IAHSP
    • KIAA1563
    • MGC87187
    • PLSJ
    see all
  • FunctionMay act as a GTPase regulator. Controls survival and growth of spinal motoneurons.
  • Involvement in diseaseDefects in ALS2 are the cause of amyotrophic lateral sclerosis type 2 (ALS2) [MIM:205100]. ALS2 is a familial form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper and lower motor neurons and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of cases leading to familial forms.
    Defects in ALS2 are the cause of juvenile primary lateral sclerosis (JPLS) [MIM:606353]. JPLS is a neurodegenerative disorder which is closely related to but clinically distinct from amyotrophic lateral sclerosis. It is a progressive paralytic disorder which results from dysfunction of the upper motor neurons of the motor cortex while the lower neurons are unaffected.
    Defects in ALS2 are the cause of infantile-onset ascending spastic paralysis (IAHSP) [MIM:607225]. IAHSP is characterized by progressive spasticity and weakness of limbs.
  • Sequence similaritiesContains 1 DH (DBL-homology) domain.
    Contains 8 MORN repeats.
    Contains 1 PH domain.
    Contains 5 RCC1 repeats.
    Contains 1 VPS9 domain.
  • Post-translational
    modifications
    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • Information by UniProt

References for Human Als2 peptide (ab22998)

ab22998 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab22998.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"